ClinicalTrials.gg
RecruitingNCT07377045Updated Oct 15, 2026

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

A Phase 1 interventional study of OMTX705 and Nab-paclitaxel + Gemcitabine in Pancreatic Adenocarcinoma Metastatic, sponsored by Oncomatryx Biopharma S.L.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Oncomatryx Biopharma S.L. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 15, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1b dose escalation trial of OMTX705, an anti-fibroblast activation protein (FAP) antibody-drug conjugate (ADC), in combination with gemcitabine/nab-paclitaxel and tislelizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma (PDAC).

The trial will be conducted in two parts (Part 1 and Part 2). Both parts will enroll participants with advanced PDAC that, in general, are eligible to receive gemcitabine/nab-paclitaxel. Part 1 is intended to determine the safe recommended dose of OMTX705 in combination with gemcitabine/nab-paclitaxel (1A) and in combination with gemcitabine/nab-paclitaxel+tislelizumab (1B). Both 1A and 1B will enroll in a standard 3+3 design. Only one dose level of OMTX705 will be selected for Part 2 by a Data Safety Monitoring Board (DSMB). In Part 2, 3 parallel randomized arms will be opened simultaneously with 1:1:1 randomization (N=15 each): OMTX705+gemcitabine/nab-paclitaxel (arm 2A), OMTX705+tislelizumab+gemcitabine/nab-paclitaxel (arm 2B) and gemcitabine/nab-paclitaxel (arm 2C, reference arm).

02

Conditions studied

  • Pancreatic Adenocarcinoma Metastatic
03

In context

Lead sponsor

Oncomatryx Biopharma S.L. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed .
  2. Male and female participant aged 18 years and older.
  3. Participants must have or cytologically confirmed PDAC: a) PDAC who have not received therapy or received 1 prior line of systemic cytotoxic therapy (Part 1 and Part 2) and if trial treatment is given in the setting; b) Non-resectable locoregional PDAC who have not received therapy or received 1 prior line of systemic cytotoxic therapy (Part 1 only); c) A previous treatment with a targeted agent (for example KRAS inhibitor in the context of a clinical trial) without chemotherapy not counted as previous line of therapy. This situation should be discussed with the medical monitor.
  4. Participants should have documented disease progression if previously locally advanced disease or be in 2nd line for stage IV or, in the opinion of the investigator, despite of lack of documented PD per image, require a change in the therapy.
  5. Participants should be considered in general eligible for standard GA, for first or second line for metastatic disease (Part 1 and 2) or as palliative therapy for non-resectable locoregional cancer (Part 1 only). Patients who received polychemotherapy (FOLFIRINOX or similar) as /adjuvant treatment and recur locally or distant \<6 months after the completion of systemic therapy, will be classified as second line.
  6. by v1.1 on CT PET/CT or magnetic resonance imaging (MRI) scan.
  7. Eastern Cooperative Group Performance () performance status 0-1.
  8. Adequate bone marrow, hepatic and renal function: a) Total ≤1.5 times (ULN) or total bilirubin n \<3.0 × ULN with direct bilirubin within normal range in participants with documented Gilbert's syndrome; b) and ALT ≤3 times ULN, (if liver metastases are present, then ≤5 times ULN is allowed); c) Serum creatinine ≤1.5 x ULN or ≥40 mL/min (measured or calculated using the Cockroft-Gault formula); d) ≥9.0 g/dL (whole or partial blood transfusions not allowed in the two previous weeks); e) ≥1.5 x 109/L (growth factors like granulocyte-colony stimulating factor are not allowed in the two previous weeks); f) count ≥100 x 109/L (platelet in the two previous weeks transfusions not allowed).
  9. Women of (WOCBP) and men with sexual partners who are WOCBP must be willing to adhere to highly effective requirements and must agree to avoid impregnating a partner or becoming pregnant, respectively, during the study, and for at least 90 days after the last dose of any IMP. Men with sexual partners who are WOCBP should adhere to contraception requirements for 180 days after the last dose of any IMP.
  10. Suitable venous access for safe drug administration and the study-required drug concentration and pharmacodynamics sampling.
  11. A valid .
  12. Pretreatment fresh biopsy is optional in Part 1 dose escalation. In Part 2, a fresh pretreatment biopsy and on-treatment is required unless biopsy is associated with significant risk and per discussion with the sponsor medical monitor (or designee).

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with OMTX705 or nab-paclitaxel for the locally advanced (adjuvant or ) for disease. Previous use of gemcitabine as radiosensitizer or as part of neoadjuvant/adjuvant therapy is allowed if the treatment was completed 6 months before consent signature. Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies including anti-cytotoxic T-lymphocyte associated protein 4, , and anti-PD-L1 therapeutic antibodies or any immune checkpoint inhibitor (except for participants to be enrolled in Part 1A).
  2. Treatment with systemic anticancer treatments, products, or major surgery within 4 weeks before the first dose of study drug or 5 half-lives, whichever is shorter. Participants should have recovered from previous treatment toxicity to Grade 1, baseline (excluding anemia, lymphopenia, alopecia, and skin pigmentation). Participants with endocrinopathies should have the replacement treatment in stable dosing.
  3. History of uncontrolled . Participants with brain metastases are allowed if they are previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery and have brain imaging during screening confirming that brain metastasis are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either MRI or CT and considered controlled with ≤10 mg/day prednisone equivalent at the time of receiving the first dose of OMTX705). For asymptomatic participants, screening brain imaging is not required.
  4. Participant has received extended field radiotherapy ≤4 weeks before the start of treatment (≤1 week for limited field radiation for palliation), and who has not recovered to Grade 1 or better from related side effects of such therapy (except for alopecia).
  5. Major surgical procedure or significant traumatic injury ≤21 days prior to ICF signature.
  6. Cardiac arrhythmias requiring anti-arrhythmic therapy. Note: pacemakers, beta blockers, or digoxin are permitted.
  7. Active infection requiring parenteral or oral antibiotics. Antibiotics given for prophylaxis are allowed. They are also allowed for minor localized infections like cystitis, amygdalates or localized skin infections.
  8. Evidence of serious uncontrolled medical disorder that, in the opinion of the investigator or medical monitor, makes it unwise for the participant to participate in the study or that might jeopardize compliance with the protocol.
  9. Drainage of ascitic or pleural fluid two or more times in the four weeks prior to the first dose of study drug or permanent drain in place (e.g., PleurX®) for ascites or pleural effusion symptom management.
  10. Placement of a biliary stent, endoscopic retrograde cholangiopancreatography (ERCP) or biliary catheterization (internal or percutaneous) procedure \<7 days before the first dose.
  11. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or compromised ability to provide written .
  12. Previous or concurrent cancer that is distinct in primary site or histology from PDAC within 3 years prior to randomization except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria]); note: all cancer treatments for cancers that were distinct in a primary site other than PDAC must be completed at least 3 years prior to signature date of the ICF.
  13. Uncontrolled or significant cardiovascular disease defined by the New York Hearth Association classification III or IV.
  14. History of cerebrovascular stroke or myocardial infarction within the previous 3 months.
  15. Grade ≥2 peripheral neuropathy.
  16. Received a within 30 days prior to first dose of study drug.
  17. Known virus surface antigen seropositive or detectable infection viral load. Note: Participants who have positive hepatitis B surface antigen antibody can be included but must have an undetectable hepatitis B viral load. Participants receiving antiviral therapy for hepatitis B virus for any reason are excluded.
  18. Participants positive for (HIV) are NOT excluded from this study, but HIV-positive participants must meet the following criteria: a) have CD4+ T-cell (CD4+) counts ≥350 cells/μL; b) have not had an opportunistic infection within the past 12 months. Participants on prophylactic antimicrobials can be included in the trial; c) should be on established antiretroviral therapy for at least four weeks; d) have an HIV viral load of less than 400 copies/mL prior to enrollment; e) known history of any other relevant congenital or acquired immunodeficiency other than HIV infection.
  19. Known or suspected allergy to study treatment or related products, and specifically participants with a prior history of life-threatening reaction to polysorbate 20.
  20. Women who are pregnant or breastfeeding or trying to become pregnant.
  21. Male participants wishing fathering children, planning for future sperm banking, or expressing concerns about sterility.
  22. Participants requiring the concomitant administration of medications that are strong inhibitors or inducers of , 2D6, 1A2, 2C9, 2B6, and 2C19. In case they are taking any of these drugs, they should be stopped at least 14 days prior to first dose.
  23. Except Part1A: History of disease requiring systemic therapy (daily prednisone equivalent doses >10 mg/day).
  24. Except Part 1A: Participants who discontinued prior treatment with any immune checkpoint due to irAEs, irrespective of grade, recovery, or need for continued therapy. Also, participants without formal due to previous irAE are not eligible if the AE has not resolved to Grade 1 or better and/or still requires steroids (>10 mg of prednisone equivalent per day) for ongoing management.
  25. Except Part 1A: participants with a history of pneumonitis/interstitial lung disease, and participants who discontinued prior immune checkpoint inhibitors due to Grade 2 myocarditis.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    Part 1A

    Part 1A limited dose escalation arm with three OMTX705 dose levels in combination with gemcitabine/nabpaclitaxel at standard of care doses (starting dose level (DL1A), 4.0 mg/kg; escalating dose level (DL2A) 7.0 mg/kg; reduction dose level (DL-1A 2.0 mg/kg))

    Drug: OMTX705 · Drug: Nab-paclitaxel + Gemcitabine

  • Experimental
    Part 1B

    Part 1B limited dose escalation arm with three OMTX705 dose levels in combination with gemcitabine/nabpaclitaxel and tislelizumab at standard of care doses (starting dose level (DL1B), 4.0 mg/kg; escalating dose level (DL2B) 7.0 mg/kg; reduction dose level (DL-1B 2.0 mg/kg))

    Drug: OMTX705 · Drug: Nab-paclitaxel + Gemcitabine · Drug: Tislelizumab (i.v. 200mg)

  • Experimental
    Arm 2A (Part 2)

    OMTX705 at the dose selected by DSMB from Part 1A arm plus gemcitabine/nab-paclitaxel at standard of care doses

    Drug: OMTX705 · Drug: Nab-paclitaxel + Gemcitabine

  • Experimental
    Arm 2B (Part 2)

    OMTX705 at the dose selected by DSMB from Part 1B arm plus gemcitabine/nab-paclitaxel and tislelizumab at standard of care doses

    Drug: OMTX705 · Drug: Nab-paclitaxel + Gemcitabine · Drug: Tislelizumab (i.v. 200mg)

  • Other
    Arm 2C (Part 2)

    Reference arm to calibrate safety and efficacy results from the two experimental arms 2A and 2B. Gemcitabine/nab-paclitaxel at standard of care doses.

    Drug: Nab-paclitaxel + Gemcitabine

Interventions

  • DrugOMTX705

    OMTX705 administered IV at 2.0, 4.0 or 7.5 mg/kg on days 1 and 8 every 21-days cycle

  • DrugNab-paclitaxel + Gemcitabine

    Drug pages: Albumin-Bound Paclitaxel · Gemcitabine

    Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 administered IV on days 1 an8 every 21 days cycle

  • Tislelizumab at 200 mg administered IV on day 1 of every 21-days cycle.

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs) during Part 1 of the study

    The nature and frequency of DLTs will be assessed.

    Time frame: At Day 1, Day 8 and Day 15 of the first 21-day cycle, and up to Day 1 of the second 21-day cycle.

  2. Number of participants with treatment emergent adverse events (TEAEs) during Part 1 of the study

    A TEAE is an AE that occurs from the first administration of the study drug up to EoT visit. They can be related to the study drug or not. Frequency, duration, and severity (per CTCAE v.5.0) of TEAEs will be assessed.

    Time frame: From Screening visit through EoT visit (up to 90±5 days after the last dose of study treatment)

  3. Changes in body temperature during Part 1 of the study

    Body temperature should be monitored during each infusion of OMTX705 as follows: on Cycle 1 and 2 before administration and every 30 (±5) minutes thereafter up to 1h ±5 minutes after the end of the infusion (EoI). From Cycle 3 onwards, it will be measured only at OMTX705 pre-dose and in case of clinical symptoms of an infusion-related reaction to document the AE.

    Time frame: At Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  4. Changes in blood pressure (BP) during Part 1 of the study

    BP will be measured in the sitting position after 5 minutes of rest. BP should be monitored during each infusion of OMTX705 as follows: on Cycle 1 and 2 before administration and every 30 (±5) minutes thereafter up to 1h ±5 minutes after the end of the infusion (EoI). From Cycle 3 onwards, it will be measured only at OMTX705 pre-dose and in case of clinical symptoms of an infusion-related reaction to document the AE.

    Time frame: At Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  5. Changes in pulse rate during Part 1 of the study

    Pulse rate will be measured in the sitting position after 5 minutes of rest. Pulse rate should be monitored during each infusion of OMTX705 as follows: on Cycle 1 and 2 before administration and every 30 (±5) minutes thereafter up to 1h ±5 minutes after the end of the infusion (EoI). From Cycle 3 onwards, it will be measured only at OMTX705 pre-dose and in case of clinical symptoms of an infusion-related reaction to document the AE.

    Time frame: At Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  6. Changes in electrocardiogram (ECG) PR interval during Part 1 of the study

    Changes in ECG assessed using a 12-lead ECG machine. In Cycle 1 and Cycle 2 ECGs will be recorded before the start of OMTX705 infusion and after the end of infusion (+15 minutes).

    Time frame: At Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  7. Changes in electrocardiogram (ECG) QRS interval during Part 1 of the study

    Changes in ECG assessed using a 12-lead ECG machine. In Cycle 1 and Cycle 2 ECGs will be recorded before the start of OMTX705 infusion and after the end of infusion (+15 minutes).

    Time frame: At Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  8. Changes in electrocardiogram (ECG) QT interval during Part 1 of the study

    Changes in ECG assessed using a 12-lead ECG machine. In Cycle 1 and Cycle 2 ECGs will be recorded before the start of OMTX705 infusion and after the end of infusion (+15 minutes).

    Time frame: At Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  9. Changes in electrocardiogram (ECG) Fridericia correction QT (QTcF) interval during Part 1 of the study

    Changes in ECG assessed using a 12-lead ECG machine. In Cycle 1 and Cycle 2 ECGs will be recorded before the start of OMTX705 infusion and after the end of infusion (+15 minutes).

    Time frame: At Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  10. Changes in concentration of serum chemistry parameters during Part 1 of the study

    The following laboratory parameters will be measured for serum chemistry: albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), total bilirubin, calcium, creatinine, magnesium, potassium, sodium, lactate dehydrogenase, C-reactive protein, creatine phosphokinase and glucose. Chemistry C1D1 blood samples may be collected within 3 days before dosing to ensure participant eligibility. If screening clinical laboratory testing was performed within 3 days before the C1D1 dose, it does not need to be repeated. Chemistry blood samples will be obtained weekly for the first 2 cycles (Day 1, 8 and 15 of Cycle 1 and Cycle 2). From Cycle 3, chemistry will be collected only on the administration days (Day 1 and Day 8). Samples can be collected and analyzed the day before.

    Time frame: At Screening visit, at Day 1, Day 8 and Day 15 of the two first 21-day cycles, and at Day 1 and Day 8 of the subsequent 21-day cycles until treatment discontinuation (average of 4 months).

  11. Changes in concentration of hematology parameters during Part 1 of the study

    The following laboratory parameters will be measured for hematology: hemoglobin, platelet count, red blood cell count , white blood cells (WBC) count and differential WBC count (absolute number). Hematology C1D1 blood samples may be collected within 3 days before dosing to ensure participant eligibility. If screening clinical laboratory testing was performed within 3 days before the C1D1 dose, it does not need to be repeated. Hematology blood samples will be obtained weekly for the first 2 cycles (Day 1, 8 and 15 of Cycle 1 and Cycle 2). From Cycle 3, hematology will be collected only on the administration days (Day 1 and Day 8). Samples can be collected and analyzed the day before.

    Time frame: At Screening visit, at Day 1, Day 8 and Day 15 of the two first 21-day cycles, and at Day 1 and Day 8 of the subsequent 21-day cycles until treatment discontinuation (average of 4 months).

  12. Treatment modifications during Part 1 of the study

    Treatment modifications are measured as percentage of relative dose intensity.

    Time frame: From Screening visit and through the study until treatment discontinuation (average of 4 months).

  13. Definition of Maximum tolerated dose (MTD) for Part 2

    MTD definition for Part 2: recommended dose will be based on MTD, or in absence of MTD based on non-DLT safety, efficacy as well as other relevant pharmacokinetics/pharmacodynamics evaluations.

    Time frame: From Screening visit and through the study until treatment discontinuation (average of 4 months).

  14. Objective response rate (ORR) during Part 2 of the study

    The ORR is defined as the proportion of participants who have a confirmed partial response (PR) or complete response (CR) to study treatment per RECIST v1.1 as determined by the investigator.

    Time frame: From Screening visit through EoT1 visit (30 ±2 days after the last dose of study treatment)

Secondary outcomes

  1. Disease control rate (DCR)

    DCR was assessed according to RECIST 1.1 criteria and defined as the proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD).

    Time frame: From Screening visit through EoT1 visit (30 ±2 days after the last dose of study treatment).

  2. Duration of response (DoR)

    DoR following following RECIST 1.1 criteria.

    Time frame: From Screening visit through EoT1 visit (30 ±2 days after the last dose of study treatment).

  3. Time to response

    Time to response following RECIST 1.1 criteria.

    Time frame: From Screening visit through EoT1 visit (30 ±2 days after the last dose of study treatment)

  4. Progression-free survival (PFS)

    Time from enrollment to disease progression or death, whichever occurred first, assessed according to RECIST 1.1 criteria. Participants who discontinue study treatment for reasons other than progression disease (PD) will continue to attend progression-free survival follow-up (PFS-FU) visits every 12 (±1) weeks from the EoT1 visit until the occurrence of PD, loss to folow-up, consent withdrawal, death, the start of subsequent systemic antineoplastic therapy, or study termination, whichever occurs first.

    Time frame: From Screening visit through the study until last PFS-FU visit (average of 4 months)

  5. Proportion of participants without progression/death

    Percentage of participants who remained alive and free of disease progression according to RECIST 1.1 criteria at each timepoint

    Time frame: At 3, 6 and 12 months

  6. Overall survival (OS)

    OS is defined as the time from enrollment to death from any cause. Participants' survival information (alive/dead and date of death) will be assessed every 3 months from the first dose of OMTX705 through participant contact (by phone or hospital visit) or at the time the death becomes known. If the site is aware that a patient is deceased, the date of death should be recorded in the eCRF without waiting for the next OS visit.

    Time frame: From Screening visit through the study until last OS-FU visit (average of 4 months)

  7. Proportion of participants alive

    Percentage of participants alive at each timepoint

    Time frame: At 3, 6, 12 and 18 months

  8. Percentage of reduction in cancer antigen 19-9 (CA19-9) from baseline upon treatment

    Changes in CA19-9 concentration from baseline upon treatment. CA19-9 will be measured locally in all participants at Screening and Day 1 of every cycle.

    Time frame: Part 1 and 2 (Arm 2A/2B): Screening and Day 1 of each 21-day cycle through the study until treatment discontinuation (average of 4 months). Part 2 (Arm 2C): Screening and Day 1 of each 28-day cycle until treatment discontinuation (average of 4 months).

  9. Quantification (titer) of anti-drug antibodies (ADAs) against OMTX705

    The formation of ADAs against OMTX705 will be assessed in blood samples collected prior to OMTX705 administration at Day 1 of each cycle, EoT1 and PFS-FU. The ADAs will be measured in a central laboratory designated by the sponsor. ADAs will not be assessed in Arm 2C.

    Time frame: Part 1 and 2 (Arm 2A/2B): At Day 1 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  10. Percentage of ADA-positive participants

    Percentage of participants who develop detectable ADAs to OMTX705. The formation of ADAs against OMTX705 will be assessed in blood samples collected prior to OMTX705 administration at Day 1 of each cycle, EoT1 and PFS-FU. The ADAs will be measured in a central laboratory designated by the sponsor. ADAs will not be assessed in Arm 2C.

    Time frame: Part 1 and 2 (Arm 2A/2B): At Day 1 of each 21-day cycle through the study until treatment discontinuation (average of 4 months).

  11. Blood concentrations of conjugated antibody

    Blood concentrations of conjugated antibody will be listed and summarized using descriptive statistics. The measurement of conjugated antibody will be performed using validated methods at a central laboratory designated by the sponsor. Plasma/serum samples will be collected in Cycle 1, Cycle 2 and Cycle 4 on: Day 1 (predose, end of infusion, 1-2 hours post-infusion and 2-4 hours post-infusion), on Day 8 (predose and end of infusion), and on Day 15 (±24 hours, cycle 1 only). No collection will be performed in Arm 2C.

    Time frame: Part 1 and 2 (Arm 2A/2B): At Day 1, Day 8 and Day 15 of Cycle 1, and at Day 1 and Day 8 of Cycle 2 and Cycle 4 (each cycle is 21 days).

  12. Blood concentrations of unconjugated payload (TAM470)

    Blood concentrations of TAM470 will be listed and summarized using descriptive statistics. The measurement of TAM470 will be performed using validated methods at a central laboratory designated by the sponsor. Plasma/serum samples will be collected in Cycle 1, Cycle 2 and Cycle 4 on: Day 1 (predose, end of infusion, 1-2 hours post-infusion and 2-4 hours post-infusion), on Day 8 (predose and end of infusion), and on Day 15 (±24 hours, cycle 1 only). No collection will be performed in Arm 2C.

    Time frame: Part 1 and 2 (Arm 2A/2B): At Day 1, Day 8 and Day 15 of Cycle 1, and at Day 1 and Day 8 of Cycle 2 and Cycle 4 (each cycle is 21 days).

  13. Number of participants with dose limiting toxicities (DLTs) during Part 2 of the study

    The nature and frequency of DLTs will be assessed.

    Time frame: Arm 2A/2C: At Day 1, Day 8 and Day 15 of the first 21-day cycle, and up to Day 1 of the second 21-day cycle. Arm 2C: At Day 1, Day 8 and Day 15 of the first 28-day cycle, and up to Day 1 of the second 28-day cycle.

  14. Number of participants with treatment emergent adverse events (TEAEs) during Part 2 of the study

    A TEAE is an AE that occurs from the first administration of the study drug up to EoT visit. They can be related to the study drug or not. Frequency, duration, and severity (per CTCAE v.5.0) of TEAEs will be assessed.

    Time frame: From Screening visit through EoT visit (up to 90±5 days after the last dose of study treatment)

  15. Changes in body temperature during Part 2 of the study

    Body temperature should be monitored during each infusion of OMTX705 as follows: on Cycle 1 and 2 before administration and every 30 (±5) minutes thereafter up to 1h ±5 minutes after the end of the infusion (EoI). From Cycle 3 onwards, it will be measured only at OMTX705 pre-dose and in case of clinical symptoms of an infusion-related reaction to document the AE.

    Time frame: Arm 2A/2B: Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months). Arm 2C: Screening visit, Day 1 and Day 8 of each 28-day cycle until treatment discontinuation (average of 4 months).

  16. Changes in blood pressure (BP) during Part 2 of the study

    BP will be measured in the sitting position after 5 minutes of rest. BP should be monitored during each infusion of OMTX705 as follows: on Cycle 1 and 2 before administration and every 30 (±5) minutes thereafter up to 1h ±5 minutes after the end of the infusion (EoI). From Cycle 3 onwards, it will be measured only at OMTX705 pre-dose and in case of clinical symptoms of an infusion-related reaction to document the AE.

    Time frame: Arm 2A/2B: Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months). Arm 2C: Screening visit, Day 1 and Day 8 of each 28-day cycle until treatment discontinuation (average of 4 months).

  17. Changes in pulse rate during Part 2 of the study

    Pulse rate will be measured in the sitting position after 5 minutes of rest. Pulse rate should be monitored during each infusion of OMTX705 as follows: on Cycle 1 and 2 before administration and every 30 (±5) minutes thereafter up to 1h ±5 minutes after the end of the infusion (EoI). From Cycle 3 onwards, it will be measured only at OMTX705 pre-dose and in case of clinical symptoms of an infusion-related reaction to document the AE.

    Time frame: Arm 2A/2B: Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months). Arm 2C: Screening visit, Day 1 and Day 8 of each 28-day cycle until treatment discontinuation (average of 4 months).

  18. Changes in electrocardiogram (ECG) PR interval during Part 2 of the study

    Changes in ECG assessed using a 12-lead ECG machine. In Cycle 1 and Cycle 2 ECGs will be recorded before the start of OMTX705 infusion and after the end of infusion (+15 minutes).

    Time frame: Arm 2A/2B: Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months). Arm 2C: Screening visit, Day 1 and Day 8 of each 28-day cycle until treatment discontinuation (average of 4 months).

  19. Changes in electrocardiogram (ECG) QRS interval during Part 2 of the study

    Changes in ECG assessed using a 12-lead ECG machine. In Cycle 1 and Cycle 2 ECGs will be recorded before the start of OMTX705 infusion and after the end of infusion (+15 minutes).

    Time frame: Arm 2A/2B: Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months). Arm 2C: Screening visit, Day 1 and Day 8 of each 28-day cycle until treatment discontinuation (average of 4 months).

  20. Changes in electrocardiogram (ECG) QT interval during Part 2 of the study

    Changes in ECG assessed using a 12-lead ECG machine. In Cycle 1 and Cycle 2 ECGs will be recorded before the start of OMTX705 infusion and after the end of infusion (+15 minutes).

    Time frame: Arm 2A/2B: Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months). Arm 2C: Screening visit, Day 1 and Day 8 of each 28-day cycle until treatment discontinuation (average of 4 months).

  21. Changes in electrocardiogram (ECG) Fridericia correction QT (QTcF) interval during Part 2 of the study

    Changes in ECG assessed using a 12-lead ECG machine. In Cycle 1 and Cycle 2 ECGs will be recorded before the start of OMTX705 infusion and after the end of infusion (+15 minutes).

    Time frame: Arm 2A/2B: Screening visit, Day 1 and Day 8 of each 21-day cycle through the study until treatment discontinuation (average of 4 months). Arm 2C: Screening visit, Day 1 and Day 8 of each 28-day cycle until treatment discontinuation (average of 4 months).

  22. Changes in concentration of serum chemistry parameters during Part 2 of the study

    The following laboratory parameters will be measured for serum chemistry: albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), total bilirubin, calcium, creatinine, magnesium, potassium, sodium, lactate dehydrogenase, C-reactive protein, creatine phosphokinase and glucose. Chemistry C1D1 blood samples may be collected within 3 days before dosing to ensure participant eligibility. If screening clinical laboratory testing was performed within 3 days before the C1D1 dose, it does not need to be repeated. Chemistry blood samples will be obtained weekly for the first 2 cycles (Day 1, 8 and 15 of Cycle 1 and Cycle 2). From Cycle 3, chemistry will be collected only on the administration days (Day 1 and Day 8). Samples can be collected and analyzed the day before.

    Time frame: At Screening visit, at Day 1, Day 8 and Day 15 of Cycle 1 and Cycle 2, and at Day 1 and Day 8 of subsequent cycles through the study until treatment discontinuation (average of 4 months) (Arm 2A/2B: each cycle is 21 days; Arm 2C: each cycle is 28 days).

  23. Changes in concentration of hematology parameters during Part 2 of the study

    The following laboratory parameters will be measured for hematology: hemoglobin, platelet count, red blood cell count , white blood cells (WBC) count and differential WBC count (absolute number). Hematology C1D1 blood samples may be collected within 3 days before dosing to ensure participant eligibility. If screening clinical laboratory testing was performed within 3 days before the C1D1 dose, it does not need to be repeated. Hematology blood samples will be obtained weekly for the first 2 cycles (Day 1, 8 and 15 of Cycle 1 and Cycle 2). From Cycle 3, hematology will be collected only on the administration days (Day 1 and Day 8). Samples can be collected and analyzed the day before.

    Time frame: At Screening visit, at Day 1, Day 8 and Day 15 of Cycle 1 and Cycle 2, and at Day 1 and Day 8 of subsequent cycles through the study until treatment discontinuation (average of 4 months) (Arm 2A/2B: each cycle is 21 days; Arm 2C: each cycle is 28 days).

  24. Treatment modifications during Part 2 of the study

    Treatment modifications are measured as percentage of relative dose intensity.

    Time frame: From Screening visit and through the study until treatment discontinuation (average of 4 months).

07

Study locations

6 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Mar 2029, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Jan 29, 2026
StartActual
Oct 28, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Hospital Universitario Vall d'Hebron (VHIO) · Barcelona, SpainNot yet recruiting→Recruiting
  • Hospital Universitario Donostia · Donostia / San Sebastian, SpainNot yet recruiting→Recruiting
  • Hospital Clínico Universitario de Santiago - CHUS · Santiago de Compostela, SpainNot yet recruiting→Recruiting
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Hospital Universitario Vall d'Hebron (VHIO) · Barcelona, SpainNot yet recruiting→Recruiting
    • Hospital Universitario Donostia · Donostia / San Sebastian, SpainNot yet recruiting→Recruiting
    • Hospital Clínico Universitario de Santiago - CHUS · Santiago de Compostela, SpainNot yet recruiting→Recruiting
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07377045
Lead sponsor
Oncomatryx Biopharma S.L.
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Oct 28, 2025
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Ignacio García Ribas, Chief Medical Officer
Contact
igarcia@oncomatryx.com
0034 946 08 70 37
Susana Román, Clinical Operations Director
Contact
sroman@oncomatryx.com
0034 946008 70 37

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion